LDLR and cardiovascular disorder: Moreover, miR-483-5p is associated with future onset of both diabetes and cardiovascular disease (Gallo et al., 2018) and increases hepatic LDL receptor levels by inhibiting PCSK9 production (Dong et al., 2020).